Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) Enterprise Value (2016 - 2025)

Editas Medicine (EDIT) has disclosed Enterprise Value for 11 consecutive years, with -$165.6 million as the latest value for Q3 2025.

  • Quarterly Enterprise Value rose 37.51% to -$165.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$165.6 million through Sep 2025, up 37.51% year-over-year, with the annual reading at -$269.9 million for FY2024, 16.46% up from the prior year.
  • Enterprise Value for Q3 2025 was -$165.6 million at Editas Medicine, up from -$178.5 million in the prior quarter.
  • The five-year high for Enterprise Value was -$165.6 million in Q3 2025, with the low at -$625.3 million in Q1 2021.
  • Average Enterprise Value over 5 years is -$373.5 million, with a median of -$344.3 million recorded in 2022.
  • The sharpest move saw Enterprise Value plummeted 50.69% in 2021, then surged 37.51% in 2025.
  • Over 5 years, Enterprise Value stood at -$499.8 million in 2021, then surged by 31.12% to -$344.3 million in 2022, then rose by 6.15% to -$323.1 million in 2023, then grew by 16.46% to -$269.9 million in 2024, then surged by 38.63% to -$165.6 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$165.6 million, -$178.5 million, and -$221.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.